Home » bowel » Recent Articles:

Irritable Bowel Syndrome Patients Not More Likely To Get Colon Cancer

March 10, 2010 Health News No Comments

Patients with irritable bowel syndrome are at no greater risk of having polyps, colon cancer or inflammatory bowel diseases than healthy people undergoing colonoscopies, according to new research published in the American Journal of Gastroenterology. “Patients and doctors get nervous about the symptoms of irritable bowel syndrome (IBS),” says William D. Chey, M.D., professor of Internal Medicine at the University of Michigan Medical School. “They think the symptoms represent something more sinister…

Go to Source… Continue reading

enGene Inc. To Present Research Data On EG-10 For Inflammatory Bowel Disease (IBD)

February 26, 2010 Health News No Comments

enGene Inc., a privately-held biotechnology company, announced that Dr. Eric Hsu, Sr. Director of Preclinical Research, is scheduled to present recent data on the use of enGene’s proprietary technology to concentrate delivery of interleukin-10 (IL-10) to the colon for treating IBD at the Canadian Association of Gastroenterology (CAG) annual scientific conference in Toronto. Selected as a “Poster of Distinction”, Dr…

Go to Source… Continue reading

Clinical Trial Launched To Test New Treatment Technique For Bowel Cancer

February 25, 2010 Health News No Comments

Cancer Research UK this week launches a new trial for patients with bowel cancer that has spread to the liver to see whether a new radiotherapy treatment technique is more effective than standard chemotherapy. Researchers at trial centres across the UK and coordinated at Oxford University will test a new treatment called Radio-embolisation, a form of internal radiotherapy that uses the tumour’s blood supply to target multiple sites of disease within the liver…

Go to Source… Continue reading

Behavioral Health Registry For Pediatric Inflammatory Bowel Disease To Be Created With NIH Grant

February 24, 2010 Health News No Comments

The National Institutes of Health has awarded a two-year development grant to researchers with Hasbro Children’s Hospital and the Bradley Hasbro Children’s Research Center to better understand the role behavioral health plays in pediatric inflammatory bowel disease (IBD), a condition that causes chronic and painful inflammation in the gastrointestinal tract…

Go to Source… Continue reading

Tioga Pharmaceuticals, Inc. Raises $18 Million To Fund Phase 3 Clinical Trial In Irritable Bowel Syndrome

February 19, 2010 Health News No Comments

Tioga Pharmaceuticals, Inc. today announced the closing of an $18 million equity financing. Current investors Forward Ventures, New Leaf Venture Partners and BB Biotech Ventures were joined by new investor Genesys Capital Partners. The proceeds will be used to fund a Phase 3 clinical trial for asimadoline for the treatment of patients with diarrhea predominant Irritable Bowel Syndrome (D-IBS). The trial, one of two registration trials required for approval in the United States, is a 600-subject randomized, double-blind, placebo-controlled, single-dose clinical trial in D-IBS patients…

Go to Source… Continue reading

New Guideline Identifies Major Risk Factors In The Development Of Colorectal Cancer In Children And Adults With Inflammatory Bowel Disease

February 17, 2010 Health News No Comments

Certain patients with inflammatory bowel disease (IBD), both ulcerative colitis and Crohn’s disease of the colon, have an increased risk of developing colorectal cancer compared to individuals without IBD. A number of factors contribute to the increase in risk, which necessitates an individualized and sensible approach to surveillance in patients, according to a new medical position statement and technical review published by the American Gastroenterological Association in its official journal, Gastroenterology…

Go to Source… Continue reading

Cancer-busting fat found in soy

February 11, 2010 Anal Cancer No Comments

A FATTY ingredient in soy may explain its ability to combat bowel cancer, research suggests. Scientists believe soy’s cancer-fighting secret is molecules called sphingadie (Source: Scotsman.com News – Health) Go to Source… Continue reading

Constipation in Children Causes, Symptoms, Diagnosis, Treatment,

January 16, 2010 Constipation No Comments

Constipation occurs commonly in children, affecting up to 10% at any given time. Still, only 3% of parents actually seek advice from the doctor for this condition. Constipation describes the infrequent passage of stools (bowel movements) or the passage of hard stools. Any definition of constipation depends upon comparison to how often the child normally passes stools and to the normal consistency of his or her stools.

Many children normally pass stools as far apart as every few days. Regardless, you should treat hard stools that are difficult to pass and those that happen only every three days as… Continue reading

Irritable Bowel Syndrome Does Not Respond To St. John’s Wort

January 6, 2010 Health News No Comments

A Mayo Clinic research study published in the January issue of the American Journal of Gastroenterology finds that St. John’s wort is not an effective treatment for irritable bowel syndrome (IBS). While antidepressants are frequently used to treat IBS, to date, no study has examined the success of using the herbal supplement St. John’s wort in treating IBS. “Our study investigated if herbal antidepressants such as St. John’s wort could benefit irritable bowel disease patients,” says Yuri Saito, M.D., M.P.H., gastroenterologist and lead physician scientist on the study…

Go to Source… Continue reading

‘Junk DNA’ Could Spotlight Breast And Bowel Cancer

January 6, 2010 Health News No Comments

Cancer Research UK funded scientists have found that a group of rogue genetic messengers, produced by DNA sequences commonly known as ‘junk DNA’, could help diagnose breast and bowel cancer. Their research is published in the journal Genomics. The researchers, led by Dr Cristina Tufarelli at the University of Nottingham, discovered that seven of these faulty genetic messengers – known as chimeric transcripts – are more common in breast cancer cells. Five were only present in breast cancer cells while two were found in both normal and breast cancer cells…

Go to Source… Continue reading

ADS:

Featured Content:

Growth Of Chronic Kidney Disease Highlights Need For Early Detection, Greater Knowledge Of Treatment Options

March 12, 2010

As the incidence of diabetes and hypertension continues to grow worldwide – and increasing numbers of patients progressing to kidney disease and kidney failure place a financial strain on public health systems – the need for early patient education about kidney disease and treatment options, including home-based treatments, has become critical. More than 240 million people have diabetes and this figure is projected to rise to 380 million by 20251. In the United States alone, 17.9 million have been diagnosed with diabetes resulting in medical and indirect costs (e.g…

Go to Source… Continue reading

Medicine Shoppe And Medicap Pharmacy Statement On Franchisee Lawsuit

March 12, 2010

Terry Burnside, general manager and senior vice president responsible for Medicine Shoppe and Medicap Pharmacy operations, today issued the following statement in response to a lawsuit filed in U.S. District Court in the Southern District of Ohio by seven Medicine Shoppe and Medicap franchisees, purporting to represent a class: Medicine Shoppe is dedicated to serving the needs of retail pharmacies and to helping them succeed. This has been true since 1970 when we began, and it is a value we hold sacred today…

Go to Source… Continue reading

Boston Scientific Announces Schedule For ACC 2010

March 12, 2010

Boston Scientific Corporation (NYSE: BSX) announced the schedule of the Company’s major events and news announcements at the 59th Annual Scientific Session of the American College of Cardiology/i2 Summit, March 13-16 in Atlanta. “We look forward to announcing 12-month results from the PERSEUS clinical program, which will provide important data on our third-generation drug-eluting stent, the TAXUS® Element™ Paclitaxel-Eluting Stent,” said Keith Dawkins, M.D., Senior Vice President and Chief Medical Officer for Boston Scientific…

Go to Source… Continue reading

Cancer Patients In Kent Gain Access To Advanced RapidArc(R) Radiotherapy Treatments From Varian

March 12, 2010

Cancer patients in Kent will gain access to advanced radiotherapy treatments with the decision by the Kent Oncology Centre to acquire two fully-equipped treatment machines from Varian Medical Systems (NYSE: VAR). The machines, due to be delivered to oncology departments in Maidstone and Canterbury in the spring, will mean these departments are among the first in the country to offer fast and efficient RapidArc® radiotherapy treatments…

Go to Source… Continue reading

Leading Varian-Equipped Proton Therapy Center Treats 100th Patient

March 12, 2010

Clinicians at the Rinecker Proton Therapy Center (RPTC) in Munich have treated their 100th patient using advanced proton therapy systems supplied by Varian Medical Systems (NYSE: VAR). The landmark treatment comes just three months after a second treatment gantry was commissioned at the center, which offers advanced pencil-beam proton scanning to cancer patients. These patients, requiring treatment for a wide range of cancers, have come from across Germany and 19 other countries, including Canada, Argentina, the UK and Switzerland…

Go to Source… Continue reading

AstraZeneca Comments On FDA Joint Advisory Committee Meeting On Post-Marketing Safety Studies For The Use Of LABAs In Asthma

March 12, 2010

On March 10-11, 2010, the Joint Advisory Committees of the U.S. Food and Drug Administration (FDA) — including the Pulmonary-Allergy Drugs and the Drug Safety and Risk Management Advisory Committees — discussed the design of post-marketing safety studies for long-acting beta-agonist (LABA)-containing products in the U.S., including SYMBICORT® (budesonide/formoterol fumarate dihydrate)…

Go to Source… Continue reading

The Results Are In: Users Of BodyMedia’s Wearable Body-Monitoring Technology Lose 3 Times More Weight

March 12, 2010

With obesity in America reaching alarming levels — across our adult and youth populations — results from a clinical trial unveiled by BodyMedia confirm that participants who used BodyMedia’s wearable body-monitoring technology either in conjunction with a group weight loss program or as part of their own self-directed program lost up to three times more weight than individuals who attempted to battle the bulge solo. BodyMedia Inc…

Go to Source… Continue reading

Newly-Published Study Reinforces Role Of Antiepileptic Drug Vimpat(R) (lacosamide) (C-V) As An Add-on Treatment That Significantly Reduces Epilepsy

March 12, 2010

UCB announced that the antiepileptic drug (AED) Vimpat® (lacosamide) (C-V) demonstrated significantly fewer partial-onset seizures versus placebo in adults living with epilepsy, according to a Phase III clinical study published online in Epilepsia. This study was one of three that supported the approval of Vimpat by the U.S. Food and Drug Administration (FDA) in 2008 for use as an add-on therapy for the treatment of partial-onset seizures in people with epilepsy who are 17 years and older. Previous studies have demonstrated that Vimpat has a novel mechanism of action…

Go to Source… Continue reading

Recent Comments:

  • symptoms of dementia: What's the difference between dementia and Alzheimers? what is the difference? I think my father may be suffering one of these? does anyone know the w...
  • rani: good blog thank 4 the info...
  • JourneyHome: McCarran-Ferguson was originally designed to empower both the federal government and the individual states so that they could act to prevent insurance...
  • Hydro Closet: Hi, I thought I would say you have a wonderful site and rich content. I bookmarked your site and have it in my reader now...looking forward to future ...
  • Allan Ono: Getting more usage from drugs already approved by the FDA for new indications seems like a very good way to expand treatment options without the hyper...